Clinical Trial Update: Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of DS-8201a in subjects with advanced solid malignant tumors has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-06-23